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Previewsenhances yields of known antibiotics, but
it induces two unknown compounds in
Strepotomyces peuceticus that could
not be detected in the absence of
ARC2. Conceivably, the expression levels
of the genes encoding those unknown
compounds are very low (i.e., nearly
silent), so that reinforcement of biosyn-
thetic process by efficient substrate
supply made it possible to detect the
products. The strategy described here
can be applicable to strains in the
absence of genome sequence informa-
tion and could facilitate the discovery
of new metabolites. As predicted theo-
retically, this approach could be
made muchmore forceful by combination
with such transcription-associated ap-
proaches as ribosome engineering,
adding N-acetylglucosamine, or LAL
regulator overexpression.
Although polyketides constitute the
majority of secondary metabolites, ami-934 Chemistry & Biology 19, August 24, 2012noglycoside and non-ribosomal peptides
are also valuable in chemotherapy. Is it
possible to develop similar approaches
for such a class of metabolites to access
the full spectrum of secondary metabo-
lites? The crucial question is why cryptic
genes are silent in the laboratory fer-
mentation conditions. Are the silent
genes expressed under the special yet-
unknown environmental conditions? If
so, do the cryptic secondary metabolites
play an intrinsic biological role(s) for
producing organisms under the special
environmental conditions? What are
such special conditions, if any? The
work by Craney et al. (2012) is clearly
an important step toward addressing
these questions.REFERENCES
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With common bacterial pathogens becoming increasingly resistant to the current therapeutic arsenal, there
is a growing need to utilize alternative strategies when developing new antibacterial drugs. In this issue of
Chemistry & Biology, Smith et al. explore the idea of antivirulence drugs by developing inhibitors of the
type IV secretion system in Brucella.Since the advent of widespread anti-
biotic use, pathogenic bacteria have
been under constant pressure to develop
resistances to commonly used antibi-
otics. The ensuing increase in antibiotic
resistance has outpaced the dwindling
production of new drugs, and this situa-
tion is rapidly endangering public health.
While existing antibiotics inhibit overall
bacterial growth by targeting essential
cellular functions, an emerging alternative
strategy targets bacterial virulence
factors without directly killing cells in the
hopes of avoiding the strong selective
pressures of current antibiotics (reviewed
by Cegelski et al., 2008). Bacterial secre-tion systems are particularly compelling
targets, and indeed, there has been sig-
nificant progress over the last decade in
the development of inhibitors of type III
secretion systems and chaperone-usher
secreted pili (Kauppi et al., 2003, Pinkner
et al., 2006). In this issue of Chemistry &
Biology, Smith et al. (2012) extend upon
their previous research to identify several
novel chemicals that bind and inactivate
the type IV secretion system (T4SS) in
Brucella.
The T4SS is capable of secreting DNA
and/or protein substrates and has impor-
tant roles in both conjugation and bacte-
rial pathogenesis. It is an important viru-lence factor of many notable human
pathogens including Helicobacter pylori,
Legionella pneumophila, Bordetella
pertussis, and Ricksettsai prowazekii,
which cause peptic ulcers, Legionnaires’
disease, whooping cough, and typhus
fever, respectively. T4SS are also utilized
by numerous animal pathogens such as
Brucella abortus and Brucella suis, which
both cause disease in cattle and pigs
but can also cause brucellosis in humans.
The T4SS found in Brucella is closely
related to that of the plant pathogen
Agrobacterium tumefaciens, one of the
best characterized T4SS model systems.
Agrobacterium is widely studied and
AB
Figure 1. Structure and Localization of the vir T4SS
(A) Model of the architecture of the T4SS. B7-B9-B10 form the
core complex (green) that spans from the inner membrane (IM)
to the outer membrane (OM). B8 homodimers (red) are posi-
tioned to allow interaction with B4 and B10. The IM-spanning
energetic complex (blue) is comprised of hexamers of B4 and
B11. The extracellular T-pilus primarily consists of B2 (gold)
with B5 (orange) at the tip. The N terminus of B1, 1-lys, cleaves
the peptidoglycan layer (green zig-zags and red crosslinks) to
allow insertion of the T4SS, and the C terminus of B1, 1*, is
required for pilus assembly. The exact localization of B3
(gray) and B6 (yellow) is not known, but both are associated
with the IM. The diagram is drawn approximately to scale;
for example, the width of the T-pilus and B11 hexamers is
10 nm, and the core complex is 18 3 18 nm.
(B) The vir T4SS is positioned periodically around the circum-
ference of Agrobacterium. T4SS foci were visualized using
a functional GFP fusion to B8. Scale bar is 2 mm.
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Previewsintensely utilized due to its ability to
transform plant cells with any gene
of interest through its virulence (vir)
T4SS. The vir-T4SS consists of 11
proteins (VirB1-11), which form
a channel spanning the cell enve-
lope and an extracellular pilus that
aids in attachment to the host cell
surface (Figure 1A). Approximately
12–14 vir-T4SS complexes are ar-
ranged periodically around the cell
perimeter (Figure 1B), likely to facili-
tate effective host cell contact and
substrate transfer through multiple
vir-T4SS complexes at a time (see
Cameron et al., 2012 and references
therein).
The structure of individual vir-
T4SS channels has been probed
by a variety of methods, including
two hybrid systems (Ward et al.,
2002) and transfer DNA immu-
noprecipitation (Cascales and
Christie, 2004); however, the most
critical contributions have come
from crystallography and cryo-elec-
tron microscopy (EM). A recently
resolved 1.05 megadalton core
complex consisting of 14 copies of
three components (VirB7, VirB9,
and VirB10) revealed an 18 nm
diameter structure spanning from
the inner to outer membranes (see
‘‘core complex’’, Figure 1A) (Fronzes
et al., 2009). Early attempts to crys-
tallize proteins from Agrobacterium
were unsuccessful due to solubility
issues, prompting researchers to
utilize a homologous conjugative
T4SS to establish the core complexstructure. Interestingly, while the VirB8
component was expressed concomitant
to VirB7, VirB9, and VirB10, it did not
associate with these proteins to form
a stable complex for cryo-EM. However,
site-specific mutations in VirB8 block
its specific interaction with VirB10 and
VirB4, suggesting it is nevertheless
centrally localized in the T4SS channel
(Figure 1A).
The VirB8 T4SS component now has
been crystallized from Brucella suis,
Agrobacterium tumefaciens, and Brucella
abortus. VirB8 has a short (40 aa)
N-terminal cytoplasmic domain, followed
by a membrane spanning region of
20 aa, and a periplasmic domain of
177 aa that forms homodimeric crystals.
Each periplasmic monomer is a singledomain of five a helices clustered to one
side of a four-strand anti-parallel b sheet,
with dimensions of 20 3 30 3 45 A˚.
Conserved residues have been mapped
to the surface and dimer interfaces (Bailey
et al., 2006, Paschos et al., 2006), and
mutagenesis studies demonstrated that
several conserved residues are important
for self-interaction or interaction with
other components of the T4SS, such as
VirB4 or VirB10 (see VirB4-VirB8-VirB10
positioning diagrammed in Figure 1A).
Importantly, when VirB8 dimerization is
perturbed, the T4SS is no longer func-
tional (Paschos et al., 2006).
In a previous study, Paschos et al.
(2011) performed an exhaustive high
throughput screen of 30,000 com-
pounds to identify 48 that specificallyChemistry & Biology 19, August 24, 2012 ª201inhibited VirB8 dimer formation as
assayed by bacterial two hybrid
interaction. The key advance in
these studies, and those now re-
ported by Smith et al. (2012), is
that the drugs target a protein
(VirB8) with a well known structure,
giving them high target specificity
for T4SS. Importantly, Paschos
et al. (2011) tested their candidate
compounds for toxicity in mam-
malian cells; one compound,
B8I-2, had negligible toxicity,
making it an excellent candidate
as an antivirulence factor. Indeed,
B8I-2 strongly reduced intracellular
survival of Brucella abortus in
macrophages.
Here, Smith et al. (2012) take
this clever structure-inspired ap-
proach further by conducting struc-
tural analyses of B8I-1 and B8I-2
binding to VirB8, confirming their
intimate docking to specific VirB8
residues. The authors expected
the compounds to bind to the
dimer interface based on their
screen; instead, the binding occurs
in a deep groove opposite to
the dimerization interface. These
latter data suggest that drug
binding may alter the VirB8 mono-
mer conformation to inhibit dimer
formation.
Besides drug design, screening,
and in silico validations of drug-
protein interaction, it is also critical
to perform large scale in vivo assays
to monitor drug efficacy and host
cytotoxicity. Furthermore, as theB8I-1/2 compounds bind to a particular
groove between the a helices and b sheet
domains, it is essential to check that
similar 3D structures do not exist in
other known proteins that may provide
essential cellular functions. Nonetheless,
we look forward to the continuing
developments of this exciting field that
holds great promise for drug design.
Drugs targeting the T4SS are especially
compelling, because they hold the po-
tential to block not only the secretion of
effectors and toxins but to also prevent
the spread of antibiotic resistance
genes by bacterial conjugation within
a patient. We hope that these and related
compounds will prove to be effective
on a wide range of divergent T4SS and
pathogens.2 Elsevier Ltd All rights reserved 935
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